Introduction
============

The biological effects of polyunsaturated fatty acids (PUFAs) have been widely investigated around the world. In particular, their impacts on human health have attracted increasing public attention in recent years. PUFAs mainly include two groups: n-3 PUFAs and n-6 PUFAs. The n-3 PUFAs have been the subject of increasing investigation and have attracted considerable interest as pharmaceutical and nutraceutical compounds ([@B01],[@B02]). n-3 PUFAs are beneficial for humans and animals and have been shown to exert preventive and therapeutic effects on some diseases such as cardiovascular diseases, arthritis, cancer, and neuropathic diseases ([@B03]-[@B05]). Supplementation of diet with n-3 PUFAs has therapeutic effects on inflammatory and autoimmune diseases such as arthritis ([@B06],[@B07]). Studies with nonhuman primates ([@B08]) and human newborns indicate that n-3 fatty acids are essential for the normal functional development of the retina and brain, particularly in premature infants ([@B09],[@B10]). Clinical cancer research indicates that breast and colon cancer can be modified or their growth can be inhibited by adding n-3 PUFAs to the human diet ([@B11]-[@B13]). n-3 PUFAs have been shown to exert anticancer activity *in vitro* and in animal models of experimental cancer ([@B14],[@B15]). In general, a balanced n-6/n-3 ratio of the body lipids is essential for normal growth and development and plays an important role in the prevention and treatment of many clinical problems ([@B16]).

However, humans and mammals are incapable of synthesizing n-3 PUFAs in their bodies, so that the levels of PUFAs in their bodies are, to a large extent, dependent on dietary intake ([@B17],[@B18]). Currently, the Western diet contains a disproportionally high amount of n-6 PUFAs and low amounts of n-3 PUFAs, which lead to much lower levels of n-3 PUFAs compared to n-6 PUFAs in mammals since the ratio of n-6 to n-3 PUFAs can be as high as 18 or even higher and is thought to contribute to cardiovascular disease, inflammation, and cancer ([@B19]). Therefore, one of the current focal points in the field of health science research is to increase n-3 PUFA content in the diet and to obtain abundant sources of n-3 PUFAs. The acquisition of proper desaturase genes to produce higher levels of n-3 PUFAs is one of the keys to solving this problem.

It is known that the n-3 fatty acid desaturase (FAD) plays an important role in the synthesis of n-3 PUFAs, since it can efficiently covert n-6 PUFAs to n-3 PUFAs. The n-6 and n-3 PUFAs are synthesized through an alternating series of desaturations and elongations beginning with either linoleic acid (LA, 18:2 n-6) or α-linolenic acid (ALA, 18:3 n-3), respectively. ALA is an essential fatty acid, which has many sanitary functions in humans. However, its content in the diet is often insufficient. In plants, n-3 FAD catalyze LA into ALA. The major end point of the n-6 pathway in mammals is arachidonic acid (AA, 20:4 n-6), and the major end-products of the n-3 pathway are eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3). The n-3 and n-6 PUFAs are not interconvertible in mammalian cells ([@B17]). Thus, LA, ALA, and their elongation and desaturation products are considered to be essential fatty acids in the human diet. The PUFA composition of cell membranes is, to a great extent, dependent on dietary intake ([@B18],[@B20]). Nevertheless, some plants, such as *Chlorella vulgaris*, are able to synthesize the n-3 fatty acid ALA. It has been reported that a CvFad3 gene from *C. vulgaris* encodes the n-3 FAD; this enzyme, when expressed in *Nicotiana tabacum*, can catalyze the conversion of n-6 PUFAs to n-3 PUFAs by introducing an n-3 double bond into their hydrocarbon chains ([@B21]).

The objective of this study was to examine whether the CvFad3 gene from *C. vulgaris* can be functionally expressed in mammalian cells in a highly efficient manner and whether its expression can exert a significant effect on cell fatty acid composition.

Material and Methods
====================

Construction of the recombinant plasmid pEGFP-C3-n-3
----------------------------------------------------

The plasmid pEGFP-C3 (BD Bioscience Clontech, USA) was digested with *Xho*I and *Eco*RI (Promega, USA), and fractionated on 1% agarose gels, and the longer band was purified. The fragment of the CvFad3 gene was amplified from mRNA of *C. vulgaris* by RT-PCR and then inserted into the plasmid of pEGFP-C3 (shown in [Figure 1](#f01){ref-type="fig"}), as described in detail below. The long segment pEGFP-C3 and the CvFad3 gene were ligated at 1:4 (mol/mol) by T4 ligase. The structure of the construct was confirmed by enzymatic digestion and DNA sequencing. The eukaryotic recombinant expression vector was named pEGFP-C3-n-3.

Figure 1.Construction of the recombinant plasmid pEGFP-C3-n-3. EGFP = enhanced green fluorescent protein; CMV = cytomegalovirus; FAD = fatty acid desaturase.

Cell cultures and transfection with recombinant plasmid
-------------------------------------------------------

MCF-7 cells were obtained from Shanghai Life Science, Chinese Academy of Sciences. MCF-7 cells were maintained routinely in a 1:1 (v/v) mixture of high glucose DMEM and 10% (v/v) fetal bovine serum at 37°C in a tissue culture incubator with 5% CO~2~ and 98% relative humidity. MCF-7 cells were added to 6-well plates and cultured by standard procedure. The cell number and medium volume were the same in each well. After 24 h of culture, cells were transfected with the recombinant plasmid pEGFP-C3-n-3 and pEGFP-C3-control for experiments to be conducted when 75% of the plate was covered with cells. Transfections were carried out by adding the Xfect polymer to the same culture medium with serum. After 5-h incubation, the transfection medium was replaced with normal culture medium. After 48-h incubation, cells were photographed and analyzed for gene expression and fatty acid composition.

Cell growth and viability assay (MTT)
-------------------------------------

Cell growth and viability were determined with the cell proliferation kit I (MTT, Roche Diagnostics Corporation, Germany). MCF-7 cells (1 × 10^4^ plaque-forming units/mL) were grown on 96-well culture plates. Two groups were set up for pEGFP-C3-n-3 and pEGFP-C3-control. Each group had 10 parallel wells. After 48 h of transfection, 20 µL MTT (5 mg/mL) labeling reagent was added to each well (100 µL medium). The plates were incubated with 50 mL/L CO~2~ at 37°C for 4 h, the medium was discarded, and 100 µL of the solubilization solution was then added to each well. Complete solubilization of the purple formazan crystals was confirmed and the absorbance of the solution at 490 nm was determined.

RNA analysis
------------

Briefly, total RNA was extracted from cultured cells, which were transfected after 48 h by using a total RNA isolation regent (Trizol, Invitrogen, USA) according to the manufacturer protocol. The CvFad3 gene fragment was amplified and the reverse transcription-polymerase chain reaction (RT-PCR) was performed. The forward and reverse primers were 5′-TTGCCGCTCCTGCCGAAGA-3′ and 5′-GGGTCACTGGGTCCGTGATGGT-3′, respectively. The conditions for amplification were 94°C for 3 min, 94°C for 30 s, 61°C for 40 s, 72°C for 1 min, and 72°C for 10 min. The amplification products were 793 bp and the band was subjected to autoradiography.

Lipid analysis
--------------

After 48 h of transfection, the MCF-7 cells were collected from 6-well plates. The fatty acid composition of total cell lipids was analyzed as described ([@B22]). Lipid was extracted with chloroform/methanol (2:1, v/v) containing 0.005% butylated hydroxytoluene as antioxidant. Fatty acid methyl esters were prepared using a 14% (w/v) BF3/methanol reagent. Fatty acid methyl esters were quantified by GC/MS using an HP-5890 Series II gas chromatograph equipped with a Supelcowax SP-10 capillary column (Supelco, USA) attached to an HP-5971 mass spectrometer. The injector and detector were maintained at 260° and 280°C, respectively. The oven program was maintained initially at 150°C for 2 min, then increased to 200°C at 10°C/min and held for 4 min, increased again at 5°C/min to 240°C and held for 3 min, and finally increased to 270°C at 10°C/min and maintained for 5 min. The carrier gas-flow rate was maintained at 0.8 mL/min. Total ion monitoring was performed, encompassing mass ranges from 50 to 550 atomic mass units. Fatty acid mass was determined by comparing the areas of the various fatty acids analyzed to the areas of a fixed concentration of the internal standard.

Measurement of eicosanoids
--------------------------

Prostaglandin E~2~ (PGE~2~) was measured with the mouse PGE~2~ ELISA kit (R&D, USA) following the manufacturer protocol. After 48-h transfection, the medium of the 3T3 cells was collected and subjected to eicosanoid measurement.

Cell cycle and apoptosis analysis
---------------------------------

After 48-h transfection, MCF-7 cells were collected from 6-well plates. Cell cycle and apoptosis were then determined using the Vybrant Apoptosis Assay Kit (Invitrogen), according to the manufacturer protocol, and measured by fluorescence-activated cell sorting using a FACScan flow cytometer (Becton Dickinson, USA).

Data analysis
-------------

Cell growth and viability data (MTT), PGE~2~ and fatty acid composition were analyzed with the GraphPad Prism 5 software. The data of cell cycle and apoptosis were analyzed with the WinMDI 2.9 software and each experiment was repeated 3 times. Data are reported as means ± SD. The data of PUFA composition were analyzed by one-way ANOVA followed by the Bonferroni *t*-test. The other data were analyzed by the Student *t*-test. The level of significance was set at P \< 0.05.

Results
=======

Enzymatic digestion of recombinant plasmid pEGFP-C3-n-3
-------------------------------------------------------

Recombinant plasmid pEGFP-C3-n-3 was digested with the fast digest *Xho*I and *Eco*RI, and the result corresponded to plasmid pEGFP-C3 and the objective CvFad3 gene (shown in [Figure 2](#f02){ref-type="fig"}).

Figure 2.Identification of the recombinant plasmids pEGFP-C3-n-3 and pEGFP-C3 by double enzyme *Xho*I/*Eco*RI digestion. *Lane M* = 1-kb DNA ladder; *lanes 1, 2, 3* = *Xho*I/*Eco*RI digest pEGFP-C3-n-3; *lane 4* = *Xho*I/*Eco*RI digest pEGFP-C3. PCR products were observed on 1.0% agarose gel electrophoresis.

Expression of the CvFad3 gene in MCF-7 cells
--------------------------------------------

The coexpression of EGFP allowed us to identify the cells that were transfected and that expressed the transgene. The result is shown in [Figure 3](#f03){ref-type="fig"}; 48 h after transfection about 40% of the cells exhibited bright fluorescence, indicating a high efficiency of gene transfer and a high expression level of the transgene.

Figure 3.Photomicrographs showing gene transfer efficiency (200X magnification). MCF-7 cells were transfected with pEGFP-C3-control or pEGFP-C3-n-3. Forty-eight hours after tranfection, many cells in the two groups exhibited bright fluorescence showing that plasmid pEGFP-C3-n-3 and pEGFP-C3 were successfully transfected into MCF-7 cells. About 40% of the cells exhibited bright fluorescence in the pEGFP-C3-n-3 group, indicating a high efficiency of gene transfer and a high expression level of the transgene.

Furthermore, the expression profile of the transgene was also determined by RT-PCR. As shown in [Figure 4](#f04){ref-type="fig"}, the mRNA of the CvFad3 gene was not detected in cells transfected with pEGFP-C3-control but was abundant in cells transfected with pEGFP-C3-n-3. The results indicate that the CvFad3 gene has a very high expression in MCF-7 cells transfected with pEGFP-C3-n-3.

Figure 4.Result of n-3 fatty acid desaturase (FAD) transcript levels in MCF-7 cells transfected with pEGFP-C3-control and pEGFP-C3-n-3 after 48 h. *Lane M* = 100-bp DNA ladder; *lane 1* = pEGFP-C3-control group; *lane 2* = pEGFP-C3-n-3 group. PCR products were observed on 2.0% agarose gel electrophoresis. This result indicates that CvFad3 mRNA was not detected in MCF-7 cells transfected with pEGFP-C3-control, but was highly abundant in MCF-7 cells transfected with pEGFP-C3-n-3.

n-3 desaturase activity and its effect on fatty acid composition
----------------------------------------------------------------

We tested whether the expression of the CvFad3 gene in MCF-7 cells can lead to conversions of n-6 fatty acids to n-3 fatty acids and, thereby, to a change in fatty acid composition. The fatty acid composition of total cellular lipids was analyzed by gas chromatography and the results were summarized in [Figure 5](#f05){ref-type="fig"} and [Table 1](#t01){ref-type="table"}. The fatty acid profiles differ remarkably between the control cells transfected only with pEGFP-C3 and the cells transfected with pEGFP-C3-n-3. In the cells expressing the CvFad3 gene, n-6 fatty acids were converted largely to the corresponding n-3 fatty acids, namely, 18:2 n-6 to 18:3 n-3, and 20:4 n-6 to 20:5 n-3. As a result, the fatty acid composition of the cells expressing the n-3 FAD was changed significantly when compared to that of the control cells transfected with pEGFP-C3-control or that of non-transfected cells ([Table 1](#t01){ref-type="table"}). Importantly, the n-6/n-3 ratio was reduced from 6:1 in the control cells to about 1:1 in the cells expressing the n-3 FAD.

Figure 5.Partial gas chromatography traces showing fatty acid profiles of total cellular lipids extracted from non-transfected cells, control cells transfected with pEGFP-C3-control and cells transfected with pEGFP-C3-n-3. *A*, Non-transfected group. *B*, pEGFP-C3-control group. *C*, pEGFP-C3-n-3 group. The fatty acid profiles in the cells transfected with the pEGFP-C3-n-3 are remarkably different from those of non-transfected cells or of the control cells transfected with the pEGFP-C3. In the cells expressing the CvFad3 gene, n-6 fatty acids were converted largely to the corresponding n-3 fatty acids, namely, 18:2 n-6 to 18:3 n-3, and 20:4 n-6 to 20:5 n-3.

Table 1.PUFA composition of total cellular lipids from the control MCF-7 cells and the transgenic cells, which express the CvFad3 gene.PUFA compositionNon-transfected groupControl groupExperimental groupn-6 PUFAs 18:2 n-65.95 ± 0.1316.02 ± 0.1562.24 ± 0.051[\*](#TFN02t01){ref-type="table-fn"}[\#](#TFN03t01){ref-type="table-fn"} 20:4 n-64.67 ± 0.0644.74 ± 0.0591.72 ± 0.049[\*](#TFN02t01){ref-type="table-fn"}[\#](#TFN03t01){ref-type="table-fn"} 22:5 n-61.94 ± 0.0371.80 ± 0.0420.87 ± 0.041[\*](#TFN02t01){ref-type="table-fn"}[\#](#TFN03t01){ref-type="table-fn"} Total12.5412.564.83n-3 PUFAs 18:3 n-30.89 ± 0.05786 ± 0.0452.95 ± 0.078[\*](#TFN02t01){ref-type="table-fn"}[\#](#TFN03t01){ref-type="table-fn"} 20:5 n-30.78 ± 0.05274 ± 0.0442.14 ± 0.056[\*](#TFN02t01){ref-type="table-fn"}[\#](#TFN03t01){ref-type="table-fn"} 20:6 n-30.52 ± 0.04147 ± 0.0321.05 ± 0.035[\*](#TFN02t01){ref-type="table-fn"}[\#](#TFN03t01){ref-type="table-fn"} Total2.192.076.14n-6/n-3 ratio5.726.070.79[^1][^2][^3]

Effect on eicosanoid production
-------------------------------

Because 20:4 n-6 (AA) and 20:5 n-3 (EPA) are the precursors of 2- and 3-series of eicosanoids, respectively, differences in the contents of AA and EPA may lead to a difference in the production of eicosanoids in the cells. Thus, we measured the production of eicosanoids in the transfected cells using an enzyme immunoassay kit. As shown in [Figure 6](#f06){ref-type="fig"}, the amount of PGE~2~ produced by the cells transfected with pEGFP-C3-n-3 was significantly lower than that of the control cells (P \< 0.05).

Figure 6.Enzyme immunoassay of prostaglandin E~2~ (PGE~2~) levels in the control cells and in the cells expressing n-3 fatty acid desaturase. 1 = pEGFP-C3-control group; 2 = pEGFP-C3-n-3 group. The level of PGE~2~ in cells transfected with pEGFP-C3-n-3 was lower than that of the control cells. ^\*^P \< 0.05 compared to control (Student *t*-test).

Change of cell proliferation
----------------------------

To investigate the effect of the expression of the CvFad3 gene on MCF-7 cell growth, we analyzed cell proliferation. As shown in [Figure 7](#f07){ref-type="fig"}, in the result of the MTT kit (cell growth and viability assay), the absorbance of control cells was higher than that of the experimental group. That is to say, the growth and viability of control cells were higher than those of experimental cells with the CvFad3 gene, because the greater the number of live cells or the lower the number of dead cells, the higher the absorbance of cells at 490 nm (P \< 0.01). This indicates that the expression of the CvFad3 gene can cause MCF-7 cells to die and/or can inhibit their growth, leading to a decrease of cell proliferation.

Figure 7.Proliferation of MCF-7 cells (the control cells and the cells expressing n-3 fatty acid desaturase) was assessed by MTT. 1 = pEGFP-C3-n-3 group; 2 = pEGFP-C3-control group. The absorbance of cells transfected with pEGFP-C3-n-3 was lower than that of the cells transfected with pEGFP-C3-control. ^\*^P \< 0.05 compared to control (Student *t*-test).

Change of cell cycle and apoptosis
----------------------------------

Compared to cells transfected with pEGFP-C3-control, in the MCF-7 cells transfected with pEGFP-C3-n-3, the percent of the G~0~/G~1~ period was lower (P \< 0.01) while the percent of the G~2~/M period was higher (P \< 0.01); the percent of the S period and APO period obviously increased (both P \< 0.01, [Figure 8](#f08){ref-type="fig"}, [Table 2](#t02){ref-type="table"}). These results indicate that the CvFad3 gene could inhibit MCF-7 cell proliferation, that the cell cycle is blocked in the G~2~/M period, and that cells could not divide subsequently. Apoptosis analysis showed that the percent of early apoptosis and late apoptosis was higher in the MCF-7 cells transfected with pEGFP-C3-n-3-control compared to cells transfected with pEGFP-C3-control (P \< 0.01, [Figure 9](#f09){ref-type="fig"}, [Table 3](#t03){ref-type="table"}).

Figure 8.Effect of transfection on the cell cycle. *A*, pEGFP-C3-control group. *B*, pEGFP-C3-n-3 group. In the MCF-7 cells transfected with pEGFP-C3-n-3, the percent of the G~0~/G~1~ and APO periods was increased (P \< 0.05 for both), while the percent of the G~2~/M and S periods was decreased (P \< 0.05 for both, Student *t*-test).

Figure 9.Effect of transfection on the cell apoptosis. *A*, pEGFP-C3-control group. *B*, pEGFP-C3-n-3 group. PI = propidium iodide; FITC = fluorescein isothiocyanate. In the MCF-7 cells transfected with pEGFP-C3-n-3, the percent of early apoptosis and late apoptosis was higher (P \< 0.01, Student *t*-test).

Table 2.Change of the control MCF-7 cells and the transgenic cells expressing the CvFad3 gene in cell cycle and apoptosis.GroupG~0~/G~1~ periodG~2~/M periodS periodAPO periodControl43.64 ± 0.311820.83 ± 0.280533.76 ± 0.10441.767 ± 0.1528Experimental53.49 ± 0.3955[\*](#TFN02t01){ref-type="table-fn"}15.47 ± 0.3676[\*](#TFN02t01){ref-type="table-fn"}25.87 ± 0.5105[\*](#TFN02t01){ref-type="table-fn"}3.200 ± 0.1000[\*](#TFN02t01){ref-type="table-fn"}[^4][^5]

Table 3.The early apoptosis and late apoptosis of the control MCF-7 cells and the transgenic cells expressing the CvFad3 gene.GroupEarly apoptosisLate apoptosisControl4.13 ± 0.1675.60 ± 0.208Experimental5.90 ± 0.100[\*](#TFN02t01){ref-type="table-fn"}6.63 ± 0.088[\*](#TFN02t01){ref-type="table-fn"}[^6][^7]

Discussion
==========

In this study, we expressed the construct in MCF-7 cells to estimate the product activity as well as the expression of the CvFad3 gene in mammals. This study has clearly demonstrated that the CvFad3 gene from *C. vulgaris* can be expressed functionally in human breast cancer cells, and its expression could confer on the cells the ability to convert n-6 PUFAs to the corresponding n-3 PUFAs, leading to a balanced n-6/n-3 ratio, that could inhibit cell growth and induce apoptosis in breast cancer cells.

We know that n-6 PUFAs stimulate animal tumors and cancer growth and metastasis, whereas n-3 PUFAs exhibit inhibitory effects. A number of studies have shown n-3 fatty acid protection in rodent models of breast cancer. These include dietary supplementation of mouse transplantable tumors and human cell xenograft models as well as chemically induced tumors in rats ([@B23]-[@B26]). Many signaling pathways that are relevant to carcinogenesis and tumor progression are differentially affected by n-3 and n-6 PUFAs. For instance, n-6 PUFA products were reported to up-regulate and activate cellular signaling mediators including protein kinase C, ras, ERK 1/2 and NF-κb, whereas n-3 PUFA products had the opposite effect. The ability of long-chain n-3 PUFAs to induce apoptosis in tumor cells has also been attributed to the increased susceptibility of these cells to lipid peroxidation ([@B27]-[@B31]). Inhibition of tumor cell growth and invasion by n-3 PUFAs in a xenograft animal model was associated with decreased cyclooxygenase-2 and PGE~2~ levels ([@B32]). Thus, n-3 PUFAs may act as natural COX "inhibitors".

Balancing the ratio of n-6/n-3 PUFAs is a significant method for controlling tumor development ([@B33]). However, the n-3 and n-6 PUFAs are not inter-convertible in the human body because mammalian cells lack the n-3 FAD. With the hectic schedule, poor dietary habits and low quality of food sources that people have today, experts recommend the consumption of nutritional dietary supplements, including fish oil supplements, which help fulfill the nutritional demand of all body organs (decreasing the intake of n-6 fatty acids and increasing the intake of n-3 fatty acids) ([@B34]). Fish oil is derived from the tissues of deep-sea oily fish, but this oily fish does not actually produce DHA/EPA fatty acids, but instead accumulates them by consuming deep-sea micro-algae that produce these fatty acids. *C. vulgaris* is one kind of deep-sea micro-alga, which contains the CvFad3 gene, encoding n-3 FAD, which can catalyze the conversion of n-6 PUFAs to n-3 PUFAs. Therefore, an alternative approach that can quickly and effectively increase cellular n-3 PUFA content and balance the n-6/n-3 ratio, without the need for a lengthy intake of fish oil supplements, would be desirable. Because the lack of an n-3 desaturase gene is the bottleneck for endogenous production of n-3 PUFAs in mammals, transfer of the n-3 desaturase gene from deep-sea micro-algae to livestock is the key to overcoming this constraint since these animals already possess most of these other desaturases and PUFA elongases ([@B35]). This assumption has been shown to be feasible in transgenic mice and pigs generated with the n-3 desaturase gene from the roundworm *Caenorhabditis elegans*. A transgenic mouse model expressing the fat-1 gene increased the ratio of n-3 and n-6 fatty acids in various tissues. In the tissues and organs of these animals, many kinds of n-3 PUFAs were produced by desaturating the corresponding n-6 PUFAs ([@B36],[@B37]).

In the present study, we used a eukaryotic recombinant expression vector to transfer the CvFad3 gene from *C. vulgaris* into human breast cancer cells, to convert n-6 PUFA into n-3 PUFA to increase the level of n-3 PUFA and the n-3/n-6 PUFA ratio, and the level of PGE~2~ was also decreased. Our experimental results showed that the transgenic construct expressed the protein of interest and the transgene product had biological activity in the transfected mammal cells. Then, we demonstrated that the CvFad3 gene from *C. vulgaris* was functionally expressed and that its product had a significant effect on the fatty acid composition. The proportion of n-6 PUFAs decreased and the proportion of n-3 PUFAs increased considerably, particularly for ALA, DHA and EPA, which correspondingly inhibited cell growth and induced apoptosis in breast cancer cells. All of these results showed that the CvFad3 gene from *C. vulgaris* possesses great value for the production of n-3 PUFAs and cancer cell suppression in transgenic MCF-7 cells.

The findings reported here suggest that gene transfer of the CvFad3 gene from *C. vulgaris* could be a desirable intervention that could quickly and effectively exert therapeutic and cancer-preventive effects of n-3 fatty acids. The molecular mechanisms, which account for these biological effects, are not completely understood. Certainly, further study in this regard is warranted.

[^1]: Data are reported as area percentage (means ± SD, N = 3). The fatty acid profiles in the cells transfected with pEGFP-C3-n-3 are remarkably different from those of non-transfected cells or those of the control cells transfected with the pEGFP-C3. In the cells expressing the CvFad3 gene, n-6 fatty acids were converted largely to the corresponding n-3 fatty acids, namely, 18:2 n-6 to 18:3 n-3, and 20:4 n-6 to 20:5 n-3. As a result, the fatty acid composition of the cells expressing the n-3 fatty acid desaturase was changed significantly when compared to that of the control cells transfected with pEGFP-C3-control. Importantly, the ratio of n-6/n-3 was reduced from 6:1 in the control cells to about 1:1 in the cells expressing the n-3 fatty acid desaturase.

[^2]: P \< 0.05 compared to control group;

[^3]: P \< 0.05 compared to the non-transfected group (one-way ANOVA followed by the Bonferroni *t*-test).

[^4]: Data are reported as means ± SD of three independent experiments. Compared with cells transfected with pEGFP-C3-control, in the MCF-7 cells transfected with pEGFP-C3-n-3, the percent of the G~0~/G~1~ period was lower, while the percent of the G~2~/M period was higher; the percent of the S period and APO period obviously increased. These results indicate that the CvFad3 gene could inhibit MCF-7 cell proliferation, that the cell cycle is blocked in the G~2~/M period, and that cells could not cleave subsequently.

[^5]: P \< 0.05 compared to control (Student *t*-test).

[^6]: Data are reported as means ± SD from three repeated experiments. Apoptosis analysis showed that the percent of early apoptosis and late apoptosis was higher in the MCF-7 cells transfected with pEGFP-C3-n-3 compared to cells transfected with pEGFP-C3-control.

[^7]: P \< 0.05 compared to control group (Student *t*-test).
